Published Studies

  • Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization

    Aids Care, 2026

    Martinez, S., Garcia-Romeu, A., Wisdom, J., Jones, J.

  • Causal Inference in Studies with Functional Unmasking: Psychedelics and Beyond

    bioRxiv, 2026

    Loewinger, G., Stensrud, M. J., Nayak, S. M., Yaden, D., Levis, A. W.

  • Exploring self-reported health behavior change following naturalistic psychedelic use

    Journal of Health Psychology, 2025

    Carvalho, L. C., Encantado, J., Moller, A. C., Cornelius, T., Marrouch, N., Johnson, M., Garcia-Romeu, A., Veiga, D., Teixeira, P. J.

  • US drug policy does not align with experts’ rankings of drug harms: a multi-criteria decision analysis

    Harm Reduction Journal, 2025

    Broman, M., Davis, A. K., Armstrong, S., Levin, A., Ahmed, K., Angarita, G. A., Arterberry, B. J., Bergeria, C., Earleywine, M., Gex, K. S., Gregoire, T., Lister, J. J., Mathai, D. S., Mehtani, N. J., Menke, N., Nichols, C. D., Shaub, H., Tackett, A. P., Weiss, B., Yalin, N., Phillips, L. D.

  • Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older

    Scientific Reports, 2025

    Baral, A., Pan, Y., Hlaing, W. M., Garcia-Romeu, A., Pinheiro, P. S., Vidot, D. C.

  • Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder

    Journal of Psychedelic Studies, 2025

    Davis, A. K., DellaCrosse, M. A., Sepeda, N. D., Levin, A. W., Cosimano, M., Shaub, H., Washington, T., Gooch, P. M., Gilead, S., Gaughan, S. J., Armstrong, S. B., & Barrett, F. S.

  • Cognitive control as a transdiagnostic mechanism of action in psychedelic effects

    Cognitive, Affective, & Behavioral Neuroscience, 2025

    Sayalı, C., Truesdale, A., Rosen, D.S.

  • Gaps in US Psychedelic Policy and How to Close Them

    JAMA Health Forum, 2025

    Propes C., Cheung K., Eisenberg M. D., Yaden D. B.

  • Provider perspectives on challenges in treatment during psychedelic therapy

    Psychopharmacology, 2025

    Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Ercal, B. C., Lenze, E. J.

  • Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases

    Schizophrenia Bulletin, 2025

    Heller, N. H. & Barrett, F. S., Buchborn, T., Collerton, D., Dupuis, D., Halberstadt, A. L., Jardri, R., Noorani, T., Preller, K. H., Taylor, J., Waters, F., Winston, B. S., Leptourgos, P.

  • Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations

    The Lancet, 2025

    Rajwani, K., Jacobs, E., Bruce, L., Hokanson, J., Almonte, M. T., Feroz, F., Waldman, E., Cheung, K., Levy, N., Savulescu, J., Singh, I., Yaden, D., Earp, B. D.

  • Diversity and disagreement: Agreeing to disagree about disagreement

    Philosophical Psychology, 2025

    Anderson, D. E., Yaden, D. B.

  • Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds

    eClinicalMedicine, 2025

    Hosein, M. M., Reid, M. J., Walser, S., Charney, S., Fonzo, G. A., Lewis, B. R., Yaden, D. B., Suppes, T., Cordner, Z. A., Barrett, F. S.

  • Psychedelics beyond medicine: Treatment, enhancement, hype, consent, and the limits of medicalization

    Philosophical Psychology, 2025

    Caraccio, M., Cheung, K., Porsdam Mann, S., Bruce, L., Jacobs, E., Villiger, D., Sandbrink, J., Register, C., Hannikainen, I. R., Høeg, M. L., Clancy, S., Rajwani, K., Gordon, E. C., Spitale, G., Levy, N., Ray, K., Celidwen, Y., Singh, I., Savulescu, J., Yaden, D. B., Earp, B. D.

  • Psychedelic Therapies: One Drug, Multiple Treatments Reply to Modesto-Lowe et al

    The Journal of Clinical Psychiatry, 2025

    Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Ercal, B. C., Lenze, E. J.

  • Neutral attitude toward the utilization of psychedelic therapy for depression in the United Kingdom population

    International Journal of Drug Policy, 2025

    Jarvis, L. O., Jack, A. H., Galbraith, N., Campbell, W. K., Weiss, B.

  • Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis

    AJOB Empirical Bioethics, 2025

    Cheung, K., Propes, C., Graziosi, M., Patch, K., Yaden, D. B.

  • Self-reported improvements in comorbid post-traumatic stress disorder symptoms, depression, anxiety, and sleep among real-world patients receiving medical ketamine: Exploring the role of adjunct therapies

    European Journal of Trauma & Dissociation, 2025

    Almog, S., Garcia-Romeu, A., Walker, K. A., Weiner, M., Berry M. S.

  • What worlds do world beliefs concern?

    The Journal of Positive Psychology, 2025

    Clifton, J. D. W., Kerry, N., Mazidi, M., Yaden, D. B.

  • Ink and Identity: Personality perceptions based on tattoos

    Journal of Research in Personality, 2025

    Soulleire, B., Chopik, W. J., Carrillo, A., Campbell, W. K., Weiss, B., Miller, J. D.

  • Psychedelics Align Brain Activity with Context

    bioRxiv, 2025

    Stoliker, D., Novelli, L., Khajehnejad, M., Biabani, M., Barta, T., Greaves, M. D., Williams, M., Chopra, S., Bazin, O., Simonsson, O., Chambers, R., Barrett, F. S., Deco, G., Preller, K. H., Carhart-Harris, R., Seth, A., Sundram, S., Egan, G. F., Razi, A.

  • Anxiety state-related task disengagement varies with trait anxiety

    bioRxiv, 2025

    Sayalı, C., Heling, E., Cools, R.

  • Detecting neuroplastic effects induced by ketamine in healthy human subjects: a multimodal approach

    bioRxiv, 2025

    Agnorelli, C., Peill, J., Sawicka, G., Kurtin, D., Shatalina, E., Ahmad, K., Wall, M. B., Rua, C., Godfrey, K., Erl, N., Searle, G., Zhou, K., Weiss, B., Fagiolini, A., Carhart-Harris, R., Matthews, P. M., Rabiner, E. A., Nutt, D., Erritzoe, D.

  • The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings

    The American Journal of Psychotherapy, 2025

    Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Ercal, B. C., Lenze, E. J.

  • Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine

    Acta Médica Portuguesa, 2025

    Mota, P., Encantado, J., Carvalho, L. C., Cunha, C., Garcia-Romeu, A., Johnson, M. W., Teixeira, P. J.

  • A Consensus Taxonomy of Altered (Nonordinary) States of Consciousness: Bringing Order to Disarray

    Psychology of Consciousness: Theory, Research, and Practice, 2025

    Cardeña, E., Berkovich-Ohana, A., Valli, K., Barttfeld, P., Gomez-Marin, A., Greyson, B., Kumar, V. K., Laureys, S., Luhrmann, T. M., Newberg, A., Preller, K. H., Putnam, F. W., Tagliazucchi, E., Walsh, R., Carter, O., Yaden, D. B.

  • Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories

    Progress in Neuropsychopharmacology & Biological Psychiatry, 2025

    Healy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia-Romeu, A., Todman, M., Varon, J., D'Andrea, W.

  • Enhanced independence: De-biasing processes in psychedelic research and beyond

    Research Ethics, 2025

    Cheung, K., Ehrenkranz, R., Yaden, D. B.

  • Response Process Evaluation (RPE) for the Mystical Experiences Questionnaire (MEQ-30)

    OSF, 2025

    Rohde, J. S., Azimi, A., Graziosi, M., Yaden, D. B., Ehrenkranz, R.

  • On Minimizing Risk and Harm in the Use of Psychedelics

    Psychiatric Research and Clinical Practice, 2025

    Evans, J., Aixalà, M., Anderson, B. T., Brennan, W., Bremler, R., Breeksema, J. J., Burback, L., Calder, A. E., Carhart-Harris, R. L., Cheung, K., Devenot, N., Gorman, I., Greń, J., Hendricks, P. S., Holoyda, B., Jacobs, E., Krecké, J., Kruger, D. J., Luke, D., Majić, T., McGuire, A. L., Mehtani, N. J., Mathai, D. S., Nash, K., Noorani, T., Palitsky, R., Robinson, O. C., Simonsson, O., Stahre, E., van Elk, M., Yaden, D. B.

  • Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners

    The Journal of Clinical Psychiatry, 2025

    Bender, D. A., Nayak, S. M., Siegel, J. S., Hellerstein, D. J., Ercal, B. C., Lenze, E. J.

  • Psychedelics as moral bioenhancers: Protocol for a scoping review of ethical arguments for and against

    Wellcome Open Research, 2025

    Streicher, S., Register, C., Lim, X., Barış, M., Porsdam Mann, S., Cheung, K., Gordon, E. C., Yaden, D. B., Savulescu, J., Earp, B. D.

  • Efficacy of psychotherapeutic interventions for prolonged grief disorder

    Journal of Affective Disorders, 2025

    Srivastava, T., Lee, K., Ehrenkranz, R., Cozzolino, P., Wise, F. A., Burns, M., McCormick, T., Yaden, D. B., Agrawal, M., Penberthy, J. K.

  • The language of religious and secular practices: A mixed-method analysis

    Psychology of Religion and Spirituality, 2025

    Graziosi, M., Goldy, S., Soleiman, K., Rohde, J., & Yaden, D. B.

  • Insights on psychedelics: A systematic review of therapeutic effects

    Neuroscience & Biobehavioral Reviews, 2025

    Kugel, J., Laukkonen, R. E., Yaden, D. B., Yücel, M., & Liknaitzky, P.

  • Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?

    NPP - Digital Psychiatry and Neuroscience, 2025

    Garcia-Romeu, A.

  • Response to the US Congress Request for Information (RFI) on psychedelic research for mental health, as submitted by the Hub at Oxford for Psychedelic Ethics

    Hub at Oxford for Psychedelic Ethics, 2025

    Cheung, K., Propes, C., Jacobs, E., Earp, B. D., Yaden, D. B.

  • Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis

    International Journal of Mental Health and Addiction, 2025

    Richard, J., Scott, J., Nayak, S.M., Sepeda, S., Lowe, M. X., Jackson, H., Garcia-Romeu, A.

  • Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use

    Journal of Psychoactive Drugs, 2025

    Mathai, D. S., Roberts, D. E., Nayak, S. M., Sepeda, N. D., Lehrner, A., Johnson, M. W., Lowe, M. X., Jackson, H., & Garcia-Romeu, A.

  • Expanded Access to Psychedelic Treatments: Comparing US and Canadian Policies

    General Psychiatry, 2025

    Richard, J., Garcia-Romeu, A., & Henningfield, J. E.

  • Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study

    Journal of Affective Disorders, 2025

    Jones, G., Lowe, M. X., Nayak, S., Sepeda, N., Kettner, H., Carhart-Harris, R., Jackson, H., & Garcia-Romeu, A.

  • Impact of psychedelics on substance craving: A systematic review

    Journal of Psychopharmacology, 2025

    Chapron, S. A., Bonazzi, G., de Ternay, J., Di Lodovico, L., Landmann, C., Nourredine, M., Salvo, F., Das, R., O’Brien, S., Sessa, B., Higbed, L., Rolland, B., Garcia-Romeu, A., Auriacombe, M.

  • Psychedelic Use and Behavioral Addictions

    Journal of Psychoactive Drugs, 2024

    Brasher, T., Rosen, D., & Spinella, M.

  • An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers

    Neuroscience Applied, 2025

    Godfrey, K., Weiss, B., Zhang, X., Spriggs, M., Peill, J., Lyons, T., Carhart-Harris, R., & Erritzoe, D.

  • Practical considerations in the establishment of psychedelic research programs

    Psychopharmacology, 2024

    Barnett, B. S., Vest, M. F., Delatte, M. S., King IV, F., Mauney, E. E., Coulson, A. J., Nayak, S. M., Hendricks, P. S., Greer, G. R., & Murnane, K. S.

  • A field-wide review and analysis of study materials used in psilocybin trials: Assessment of two decades of research

    Psychedelic Medicine (2025)

    Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R., Ching, T. H. W., Cosimano, M. P., Danforth, A., Davis, A. K., Garcia-Romeu, A., Griffiths, R., Grob, C. S., Gründer, G., Gukasyan, N., Heinzerling, K. G., Hendricks, P. S., Holze, F., Horton, D. M., Johnson, M. W., Kelmendi, B., Peck, S. K., Koslowski, M., Liechti, M. E., Mertens, L. J., Moreno, F. A., Nayak, S. M., Nicholas, C. R., Preller, K. H., Rieser, N. M., Ross, S., Sergi, K., Sloshower, J., Smigielski, L., Stenbæk, D. S., Vollenweider, F. X., Weiss, B., Wolff, M., & Yaden, M. E.

  • Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism

    American Journal of Bioethics, 2025

    Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B.

  • Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review

    Current Addiction Reports, 2025

    Richard, J. & Garcia-Romeu, A.

  • Associations between psychedelic use and cannabis use disorder in a nationally representative sample

    Drug and Alcohol Dependence, 2025

    Zech, J. M., Yaden, D. B., & Jones, G. M.

  • Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples

    PLoS ONE, 2024

    Graziosi, M., Rohde, J. S., Lake, S., Lucas, P., Kaufman, S. B., & Yaden, D. B.

  • Commentary: A framework for assessment of adverse events in psychedelic research

    Journal of Psychopharmacology, 2024

    Cheung, K., Ehrenkranz, R., Hinkle, J. T., & Yaden, D. B.

  • Psychedelic risks and benefits: A cross-sectional survey study

    Journal of Psychopharmacology, 2024

    Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R., Levine, M., Barrett, F. S., & Yaden, D. B.

  • Preliminary evidence of sleep improvements following psilocybin administrations, and their involvement in antidepressant therapeutic action

    Current Psychiatry Reports, 2024

    Reid, M. J., Kettner, H., Blanken, T. F., Weiss, B., & Carhartt-Harris, R.

  • Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI

    Neuron, 2024

    Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., Zanni, G., Balakrishnan, A., Chaudhari, P. R., Pradhan, A., Suryavanshi, S., Bath, K. G., Ansorge, M. S., Fernandez-Ruiz, A., Kwan, A. C., & Vaidya, V. A.

  • Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals

    Scientific Reports, 2024

    Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A.

  • Moral attitudes toward pharmacologically assisted couples therapy: An experimental bioethics study of real-world "Love drugs"

    AJOB Neuroscience, 2024

    Buyukbabani, M. B., Earp, B. D., Hannikainen, I., Barba, T., Mihailov, E., Yaden, D. B., & Savulescu, J.

  • Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial

    eClinicalMedicine, 2024

    Erritzoe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Murphy-Beiner, A., Jones, M. B., Nutt, D., Weiss, B., & Carhart-Harris, R.

  • The Epidemiology of Psychedelic Use Among United States Military Veterans

    Journal of Psychoactive Drugs, 2024

    Davis, A. K., Bates, M., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., Koffman, R., Hooyer, K., & Yehuda, R.

  • Adverse Events Should Not Be Surprising in Psychedelic Research

    Psychedelic Medicine, 2024

    Ehrenkranz, R., Agrawal, M., Nayak, S. M., & Yaden, D. B.

  • Adverse Events in Studies of Classic Psychedelics

    JAMA Psychiatry, 2024

    Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B.

  • Clinically relevant acute subjective effects of psychedelics beyond mystical experience

    Nature Reviews Psychology, 2024

    Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R.

  • Considering distinct positive emotions in psychedelic science

    International Review of Psychiatry, 2024

    Goldy, S. P., Hendricks, P. S., Keltner, D., & Yaden, D. B.

  • Teaching a new dog old tricks: bringing rigor, grounding, and specificity to psychedelic neuropsychopharmacology

    Neuropsychopharmacology, 2024

    Heller, N. H. & Barrett, F. S.

  • Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery

    Therapeutic Advances in Psychopharmacology, 2024

    VanderZwaag, B., Garcia-Romeu, A., & Garcia-Barrera, M. A.

  • Unveiling the underlying structure of awe in virtual reality and in autobiographical recall: An exploratory study

    Scientific Reports, 2024

    Chirico, A., Borghesi, F., Yaden, D. B., Pizzolante, M., Sarcinella, E. D., Cipresso, P., & Gaggioli, A.

  • The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experience

    Principles of Addiction Medicine, 2024

    Van Elk, M., & Yaden, D. B.

  • Psychedelic medicine in psychiatry residency training: A survey of psychiatric residency program directors

    International Review of Psychiatry, 2024

    Yaden, M. E., Ching, T. H., Goldway, N., Roberts, D. E., Hokanson, J., Gukasyan, N., Pittenger, C., Kelmendi, B., Ross, S., Glick, G., & O’Donnell, K. C.

  • The pharmacology of hallucinogens

    Principles of Addiction Medicine, 2024

    Yaden, D. B., Mathai, D., Bogenschutz, M., & Nichols, D. E.

  • Belief change and agnostic frames in psychedelic research and clinical contexts

    Philosophy and the psychedelic renaissance, 2024

    Yaden, D. B., Nayak, S. M., Griffiths, R. R.

  • Understanding therapeutically relevant acute subjective effects of psychedelics

    Nature Reviews Psychology, 2024

    Yaden, D. B., Goldy, S., Weiss, B., & Griffiths, R. R.

  • Adverse events should not be surprising in psychedelic research

    Psychedelic Medicine, 2024

    Ehrenkranz, E., Agrawal, M., & Yaden, D. B.

  • Adverse events in studies of classic psychedelics: A systematic review and meta-analysis

    JAMA Psych, 2024

    Hinkle, J., Graziosi, M., Nayak, S., & Yaden, D. B.

  • Psychedelics and well-being

    Psychedelic Medicine, 2024

    Ehrenkranz, R., Graziosi, M., & Yaden, D. B.

  • Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.

    EClinicalMedicine, 2024

    Hughes, M. E., & Garcia-Romeu, A.

  • Impact of psilocybin on peripheral cytokine production

    Psychedelic Medicine, 2024

    DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher-Stine, L., & Griffiths, R. R.

  • Seeing the forest for the trees: An ecological systems theory approach to addressing emergent issues in psychedelic-assisted therapy research

    Journal of Psychedelic Studies, 2024

    DellaCrosse, M. A., Garcia-Romeu, A., & Davis, A. K.

  • Psychedelic group-based integration: Ethical assessment and initial recommendations

    International Review of Psychiatry, 2024

    Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B.

  • Psychiatric Applications of Psychedelics: Neurobiological Foundations for Treatments of Depression, Anxiety, and Obsessive-Compulsive Disorder

    Advances in Psychiatry and Behavioral Health, 2024

    Tiwari, P., Ehrenkranz, R., & Yaden, D. B.

  • Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement

    JAMA Network Open, 2024

    McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B.

  • Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder

    International Review of Psychiatry, 2024

    Ehrenkranz, R., Agrawal, M., J. Kim Penberthy, & Yaden, D. B.

  • Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study

    Journal of Psychoactive Drugs, 2024

    Nayak, S. M., White, S. H., Hilbert, S. N., Lowe, M. X., Jackson, H., Griffiths, R. R., Garcia-Romeu, A., & Yaden, D. B.

  • In Memoriam: Roland R. Griffiths (July 19, 1946–October 16, 2023)

    Journal of Psychoactive Drugs, 2024

    Henningfield, J. E., Belouin, S. J., Yaden, D. B., Urrutia, J., Anderson, B. T., Berger, A., Grob, C. S., Labate, B. C., Maier, L. J., M Catherine Maternowska, Weichold, F., & Magar, V.

  • The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement

    The American Journal of Bioethics, 2024

    Jacobs, E., Earp, B. D., Appelbaum, P. S., Bruce, L., Cassidy, K., Celidwen, Y., Cheung, K., Clancy, S. K., Devenot, N., Evans, J., Lynch, H. F., Friesen, P., Garcia-Romeu, A., Gehani, N., Maloof, M., Marcus, O., Martin Moen, O., Mertens, M., Nayak, S. M., Noorani, T., … Yaden, D. B.

  • Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression

    Psychoactives, 2024

    Meling, D., Ehrenkranz, R., Nayak, S. M., Aicher, H. D., Funk, X., Van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B

  • Psychedelics, OCD and related disorders: A systematic review

    Journal of Obsessive-Compulsive and Related Disorders, 2024

    Graziosi, M., Rohde, J. S., Tiwari, P., Siev, J., & Yaden, D. B.

  • The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

    PLoS ONE, 2024

    Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K.

  • The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item

    Psychedelic Medicine, 2024

    Strickland, J. C., Garcia-Romeu, A., Johnson, M. W.

  • Valuing the Acute Subjective Experience

    Perspectives in Biology and Medicine, 2024

    Cheung, K., Earp, B. D., & Yaden, D. B.

  • Strong bipartisan support for controlled psilocybin use as treatment or enhancement in a representative sample of US Americans: Need for caution in public policy persists

    AJOB Neuroscience, 2024

    Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., & Earp, B. D.

  • Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide’s Risk Profile More Favorably?

    Psychedelic Medicine, 2024

    Barnett, B. S., Anand, A., Dewey, E. N., Smith, D., Nayak, S. M., Bruckman, D., & Weleff, J.

  • Commentary: On the need for metaphysics in psychedelic therapy and research

    Frontiers in Psychology, 2024

    Cheung, K., & Yaden, D. B.

  • Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

    International Journal of Mental Health and Addiction, 2024

    Weiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris R. L., Erritzoe, D.

  • Psychiatric risks for worsened mental health after psychedelic use

    Journal of Psychopharmacology, 2024

    Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., Carhart-Harris, R. L.

  • Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality

    Neuroscience and Biobehavioral Reviews, 2024

    Solaja, I., Haldane, K., Mason, N., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., Bayes, A., Loo, C. K., Martin, D. M.

  • Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

    Frontiers in Psychiatry, 2024

    James, E., Erritzoe, D., Benway, T., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B. M., Barba, T., Campbell, G., Jones, M. B., Hughes, C., Topping, H., Boyce, M., Routledge, C.

  • Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression

    Psychological Medicine, 2024

    Szigeti, B., Weiss, B., Rosas, F. E., Erritzoe, D., Nutt, D., Carhart-Harris, R.

  • IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models

    Pharmacological Research, 2024

    Yaden, D. B., Berghella, A. P., Hendricks, Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., Garcia-Romeu, A.

  • Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues’ Commentary on Psilocybin-Assisted Therapy

    The American Journal of Psychiatry, 2024

    O’Donnell, K. C., Anderson, B. T., Barrett, F. S., Bogenschutz, M. P., Grob, C. S., Hendricks, P. S., Kelmendi, B., Nayak, S. M., Nicholas, C. R., Paleos, C. A., Stauffer, C. S., & Gukasyan, N.

  • Psychedemia: Charting the future of interdisciplinary Psychedelic Studies: Introduction to the Special Issue

    Journal of Psychedelic Studies, 2023

    Devenot, N., Pace, B. A., Slot, J., & Davis, A. K.

  • Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer

    Cancer, 2023

    Thrul, J., Kozak, Z., Carducci, M. A., Garcia-Romeu, A., & Yaden, D. B.

  • Development of the Japanese version of the Challenging Experience Questionnaire

    Neuropsychopharmacology Reports, 2024

    Tani, H., Yonezawa, K., Kusudo, K., Barrett, F. S., Nakajima, S., Uchida, H.

  • Effects of savoring meditation on positive emotions and pain-related brain function: A mechanistic randomized controlled trial in people with rheumatoid arthritis

    The Journal of Pain, 2024

    Finan, P. H., Hunt, C., Keaser, M. L., Smith, K., Lerman, S., Bingham, C. O., Barrett, F., Garland, E. L., Zeidan, F., Seminowicz, D. A.

  • Unique effects of sedatives, dissociatives, psychedelics, stimulants, and cannabinoids on episodic memory: A review and reanalysis of acute drug effects on recollection, familiarity, and metamemory

    Psychological Review, 2024

    Doss, M. K., Samaha, J., Barrett, F. S., Griffiths, R. R., de Wit, H., Gallo, D. A., & Koen, J. D.

  • Reply to “Capturing Synergy Holistically in Psychedelic Clinical Trials”

    Clinical Pharmacology & Therapeutics, 2023

    Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C.

  • Ayahuasca in the Treatment of Posttraumatic Stress Disorder: Mixed-Methods Case Series Evaluation in Military Combat Veterans

    Psychological Trauma: Theory, Research, Practice, and Policy, 2023

    Weiss, B., Dinh-Williams, L.-A. L., Beller, N., Raugh, I. M., Strauss, G. P., & Campbell, W. K.

  • Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

    Journal of Psychedelic Studies, 2023

    Weiss, B., Sleep, C. E., Beller, N. M., Erritzoe, D., & Campbell, W. K.

  • De-Siloing the Psychology of Religion and Psychedelic Science: Introduction to the Special Issue on Psychedelics and Mystical-type Experiences

    The International Journal for the Psychology of Religion, 2023

    van Elk, M., & Yaden, D.

  • Acute psychedelic effects and clinical outcomes are associated with therapeutic alliance among participants receiving psilocybin therapy

    Drug and Alcohol Dependence, 2024

    Davis, A., Levin, A., Lancelotta, R., Sepeda, N., Gukasyan, N., Nayak, S., Barrett, F. S., Griffiths, R.

  • The psychedelic effects of cannabis: A review of the literature

    Journal of Psychopharmacology, 2023

    Wolinsky, D., Barrett, F. S., & Vandrey, R.

  • Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts

    Journal of psychoactive drugs, 2023

    Graziosi, M., Singh, M., Nayak, S. M., & Yaden, D. B.

  • Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?

    Clinical Pharmacology & Therapeutics, 2023

    Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C.

  • Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health

    Journal of psychoactive drugs, 2023

    Urrutia, J., Anderson, B. T., Belouin, S. J., Berger, A., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., Weichold, F., Yaden, D. B., & Magar, V.

  • Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

    Frontiers in Psychiatry, 2023

    Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., Barrett, F. S., Griffiths, R. R., Strickland, J. C., Johnson, M. W., Jackson, H., & Garcia-Romeu, A.

  • Single-Dose Psilocybin Treatment for Major Depressive Disorder

    JAMA, 2023

    Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., Nicholas, C. R., Hutson, P. R., Tarpley, G., Utzinger, M., Lenoch, K., Warchol, K., Gapasin, T., Davis, M. C., Nelson-Douthit, C., Wilson, S., Brown, C., Linton, W., Ross, S., & Griffiths, R. R.

  • Predictors of psychedelic treatment outcomes among special operations forces veterans

    Psychology of Consciousness: Theory, Research, and Practice, 2023

    Xin, Y., Armstrong, S. B., Averill, L. A., Sepeda, N., & Davis, A. K.

  • Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers

    Psychedelic Medicine, 2023

    Mathai, D. S., Hilbert, S., Sepeda, N. D., Strickland, J. C., Griffiths, R. R., & Garcia-Romeu, A.

  • Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies

    The Lancet Psychiatry, 2023

    Medeiros, G. C., Matheson, M., Demo, I., Reid, M. J., Matheson, S., Twose, C., Smith, G. S., Gould, T. D., Zarate, C. A., Barrett, F. S., & Goes, F. S.

  • Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States

    Journal of Pyschedelic Studies, 2023

    Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J. C., Luoma, J., Nagib, P., Pilecki, B., & Davis, A. K.

  • The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer’s Disease

    Current Geriatric Reports, 2023

    Steinberg, M., Rosenberg, P. & Garcia-Romeu, A.

  • Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis

    Psychiatry Research, 2023

    Simonsson, O., Carlbring, P., Carhart-Harris, R., Davis, A. K., Nutt, D. J., Griffiths, R. R., Erritzoe D., & Goldberg, S. B.

  • What Is in a Name? The Many Meanings of “Psychedelic”

    Psychedelic Medicine, 2023

    O'Donnell, K., Roberts, D., Ching, T., Glick, G., Goldway, N., Gukasyan, N., Hokansen, J., Kelmendi, B., Ross, S., Yaden, M. & Pittenger, C.

  • Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences

    Journal of psychoactive drugs, 2023

    Davis, A. K., Timmermann, C., Ortiz Bernal, A. M., Lancelotta, R., Nayak, S., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R.

  • Psilocybin’s effects on cognition and creativity: A scoping review

    Journal of Psychopharmacology, 2023

    Bonnieux, J., VanderZwaag, B. & Garcia-Romeu, A. & Garcia-Barrera, M.

  • Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico

    The American Journal of Drug and Alcohol Abuse, 2023

    Davis, A. K., Xin, Y., Sepeda, N. D., & Averill, L. A.

  • The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review

    Neuroscience and Biobehavioral Reviews, 2023

    Doss, M. K., de Wit, H., & Gallo, D. A.

  • Corrigendum to 'Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity'

    NeuroImage, 2023

    Gaddis, A., Lidstone, D. E., Nebel, M. B., Griffiths, R. R., Mostofsky, S. H., Mejia, A. F., & Barrett, F. S.

  • Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation

    Cambridge Quarterly of Healthcare Ethics, 2023

    Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B.

  • Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

    Psychedelic Medicine, 2023

    Tiwari, P., Berghella, A., & Sayali, C., Doss, M., Barrett, F. S., & Yaden, D. B.

  • Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada

    Journal of Substance Use and Addiction Treatment, 2023

    Haeny, A. M., Lopez, J., Colon-Grigas, P., Crouch, M., Davis, A. K., Williams, M. T.

  • Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

    Journal of Psychopharmacology, 2023

    Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., Nayak, S. M.

  • Control Conditions in Randomized Trials of Psychedelics: An ACTTION Systematic Review

    Journal Clinical Psychiatry, 2023

    Nayak S. M., Bradley M. K., Kleykamp B. A., Strain, E. C., Dworkin, R. H., Johnson, M. W.

  • As without, so within: how the brain's temporo-spatial alignment to the environment shapes consciousness

    Interface Focus, 2023

    Northoff, G., Klar, P., Bein, M. & Safron, A.

  • Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?

    Clinical Chemistry, 2023

    Cotten, S. W., Strathmann, F. G., Barrett, F. S., Labay, L., Mullally, J., Sherwood, A. M., & Wiegand, F.

  • Cognitive Science Below the Neck: Toward an Integrative Account of Consciousness in the Body

    Cognitive Science, 2023

    Christov-Moore, L., Jinich-Diamant, A., Safron, A., Lynch, C., & Reggente, N.

  • Toward a Broader Psychedelic Bioethics

    AJOB Neuroscience

    Jacobs, E., Yaden, D., & Earp, B. D.

  • Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms

    Journal of Affective Disorders, 2023

    Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K.

  • Cultural dissonance and consonance in mystical-type experiences: commentary on “Finding consonance: an integrative neurocognitive model of human relationships with supernatural agents”

    Religion, Brain & Behavior, 2023

    Yaden, D. B. & van Elk, M.

  • A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression

    Psychedelic Medicine, 2023

    Nayak, S. M., Bari, B. A., Yaden, D. B., Spriggs, M. J., Rosas, F. E., Peill, J. M., Giribaldi, B., Erritzoe, D., Nutt, D. J. & Carhart-Harris, R.

  • The costs and benefits of psychedelics on cognition and mood

    Neuron, 2023

    Sayali, C. & Barrett, F. S.

  • Psychedelic Identity Shift: A Critical Approach to Set And Setting

    Kennedy Institute of Ethics Journal, 2023

    Devenot, N., Seale-Feldman, A., Smith, E., Noorani, T., Garcia-Romeu, A., & Johnson, M. W.

  • Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine

    Psychopharmacology, 2023

    Mathai, D. S., Nayak, S.M., Yaden, D. B., & Garcia-Romeu, A.

  • Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans

    Military Psychology, 2023

    Armstrong, S. B., Xin, Y., Sepeda, N. D., Polanco, M., Averill, L. A., Davis, A. K.

  • Does the trip matter? Investigating the role of the subjective effects of psychedelics in persisting therapeutic effects

    Neuropsychopharmacology, 2023

    Nautiyal, K. M., Yaden, D. B.

  • Editorial: The psychotherapeutic framing of psychedelic drug administration

    Frontiers in Psychology, 2023

    Beckman, M., Poulsen, S., Doss, M. K., & Stenbæk, D. S.

  • Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series

    Journal of Psychoactive Drugs, 2023

    Gukasyan, N. & Narayan, S. K.

  • Belief changes associated with psychedelic use

    Journal of Psychopharmacology, 2023

    Nayak, S. M., Singh, M., Yaden D. B., & Griffiths R.R.

  • Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder

    JAMA Psychiatry, 2023

    Kiluk, B. D., Kleykamp, B. A., Comer, S. D., Griffiths, R. R., Huhn, A. S., Johnson, M. W., Kampman, K. M., Pravetoni, M., Preston, K. L., Vandrey, R., Bergeria, C. L., Bogenschutz, M. P., Brown, R. T., Dunn, K. E., Dworkin, R. H., Finan, P. H., Hendricks, P. S., Houtsmuller, E. J., Kosten, T. R., Lee, D. C., Levin, F. R., McRae-Clark, A., Raison, C. L., Rasmussen, K., Turk, D. C., Weiss, D. R., Strain, E. C.

  • On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression

    Med, 2023

    Gukasyan, N.

  • Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

    Frontiers in Psychiatry, 2022

    Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. L., & Davis, A. K.

  • Ethical Issues Regarding Nonsubjective Psychedelics as Standard of Care

    Cambridge Quarterly of Healthcare Ethics, 2022

    Yaden, D. B., Earp, B. D., & Griffiths, R. R.

  • Integrated world modeling theory expanded: Implications for the future of consciousness

    Frontiers in Computational Neuroscience, 2022

    Safron, A.

  • Psychedelic-Assisted Therapy for People with Eating Disorders

    Current Psychiatry Reports, 2022

    Gukasyan, N., Schreyer, C. C., Griffiths, R. R., & Guarda, A. S.

  • Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling

    Neuropharmacology, 2022

    Henningfield, J. E., Coe, M.A., Griffiths, R.R., Belouin, S. J., Berger, A., Coker, A. R., Comer, S. D., Heal, D. J., Hendricks, P. S., Nichols, C. D., Sapienza, F., Vocci, F. J., & Zia, F. Z.

  • Past, Present, and Future of Psychedelics: A Psychedelic Medicine Roundtable Discussion

    Psychedelic Medicine, 2022

    Hendricks, P., Nichols, C., Cunningham, K, Geyer, M., Griffiths, R. R., Nichols, D.

  • Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity

    NeuroImage, 2022

    Gaddis, A., Lidstone, D. E., Nebel, M., Griffiths, R. R., Mostofsky, S. H., Mejia, A., & Barrett, F. S.

  • Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States

    International Journal of Drug Policy

    Levin, A., Nagib, P. B., Deiparine, S., Gao, T., Mitchell, J., & Davis, A. K.

  • A role for the claustrum in cognitive control

    Trends in Cognitive Sciences, 2022

    Madden, M. B., Stewart, B. W., White, M. G., Krimmel, S. R., Qadir, H., Barrett, F. S., Seminowicz, D. A., & Mathur, B. N.

  • Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder

    Journal of Psychedelic Studies, 2022

    Clifton, J. M., Belcher, A. M., Greenblatt, A. D., Welsh, C. M., Cole, T. O., & Davis, A. K.

  • Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care

    Neuropharmacology, 2022

    Ross, S., Agrawal, M., Griffiths, R. R., Grob, C., Berger, A., & Henningfield, J. E.

  • Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review

    Neuroscience & Biobehavioral Reviews, 2022

    van Elk, M. & Yaden, D. B.

  • Predictors of attitudes toward psychedelics among psychologists in the USA

    Drugs: Education, Prevention and Policy, 2022

    Luoma, J. B., Pilecki, B., Davis, A. K. & Smith, S. M.

  • Comparative Pharmacology and Circuit-Level Models of the Effects of Psychedelic Drugs on the Human Brain

    Biological Psychiatry Cognitive Neuroscience and Neuroimaging, 2022

    Barrett, F. S.

  • Preparing for the Bursting of the Psychedelic Hype Bubble

    JAMA Psychiatry, 2022

    Yaden, D. B., Potash, J. B., & Griffiths, R. R.

  • Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying

    PLOS ONE, 2022

    Sweeney, M. M., Nayak, S., Hurwitz, E. S., Mitchell, L. N., Swift, T. C., & Griffiths, R. R.

  • Acute and enduring effects of naturalistic psychedelic use among Indigenous peoples in Canada and the United States

    Canadian Psychology / Psychologie canadienne, 2022

    de la Salle, S., Gran-Ruaz, S., Davis, D. D., Davis, A. K., & Williams, M. T.

  • Skepticism about Recent Evidence That Psilocybin “Liberates” Depressed Minds

    ACS Chemical Neuroscience, 2022

    Doss, M. K., Barrett, F. S., & Corlett, P. R.

  • The conundrum of therapeutic intoxication

    The British Journal of Psychiatry, 2022

    Mathai, D. & Yaden, D. B. & O’Donnell, K.

  • Mapping consent practices for outpatient psychiatric use of ketamine

    Journal of Affective Disorders, 2022

    Mathai, D. S., Lee, S. M., Mora, V., O’Donnell, K. C., Garcia-Romeu, A., & Storch, E. A.

  • Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations

    Neuropharmacology, 2022

    Ortiz, C. E., Dourron, H. M., Sweat, N. W., Garcia-Romeu, A., MacCarthy, S., Anderson, B. T., & Hendricks, P. S.

  • Applying Lessons From Cannabis to the Psychedelic Highway: Buckle Up and Build Infrastructure

    JAMA Health Forum, 2022

    Boehnke, K. F., Davis, A. K., & McAfee, J.

  • Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses

    Neuroscience & Biobehavioral Reviews, 2022

    McCulloch, D. E., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., Mason, N. L., Müller, F., & Fisher, P. M.

  • The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

    Journal of Neurochemistry, 2022

    Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G.

  • Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience

    Scientific Reports, 2022

    Lawrence, B. W., Carhart-Harris, R., Griffiths, R. R., & Timmermann, C.

  • Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default

    Frontiers in Psychology, 2022

    Yaden, D. B., Earp, D., Graziosi, M., Friedman-Wheeler, D., Luoma, J. B., & Johnson, M. W.

  • The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

    Frontiers in Psychology, 2022

    Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J.

  • Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies

    JAMA Psychiatry, 2022

    Bradberry, M. M., Gukasyan, N., Raison, C. L.

  • A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities

    Frontiers in Psychology, 2022

    Nayak, S. M., & Griffiths, R. R.

  • Toward Synergies of Ketamine and Psychotherapy

    Frontiers in Psychology, 2022

    Mathai, D. S., Mora, V., & Garcia-Romeu, A.

  • Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019

    Frontiers in Epidemiology, 2022

    Davis, A. K., Aterberry, B. J., Xin, Y., Agin-Liebes, G., Schwarting, C., & Williams, M. T.

  • Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

    Journal of Psychopharmacology, 2022

    Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R.

  • Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature

    Current Topics in Behavioral Neurosciences, 2022

    Golden, T. L., Magsamen, M., Sandu, C. C., Roebuck, G. M., Shi, K. M., & Barrett, F. S.

  • Dream to Explore: 5-HT2a as Adaptive Temperature Parameter for Sophisticated Affective Inference

    Machine Learning and Principles and Practice of Knowledge Discovery in Databases, 2022

    Safron, A., & Sheikhbahaee, Z.

  • Models of psychedelic drug action: modulation of cortical-subcortical circuits

    Brain, 2022

    Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M., Griffiths, R. R., Mathur, B. N., & Barrett, F. S.

  • Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans

    Journal of Psychedelic Studies, 2022

    Mangini, P., Averill, L. A., & Davis, A. K.

  • On the Importance of Being Flexible: Dynamic Brain Networks and Their Potential Functional Significances

    Frontiers in Systems Neuroscience, 2022

    Safron, A, Klimaj, V, Hipólito, I.

  • Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation

    Frontiers in Neuroergonomics, 2022

    Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J. M., Smith, G. S., Griffiths, R. R., & Wong, D. F.

  • The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects

    Journal of Psychopharmacology, 2022

    Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D., Dolan, S. B., Lancelotta, R., Timmermann, C., Ramaekers, J. G.

  • Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials

    The Journal of Clinical Psychiatry, 2022

    Zeifman, R. J., Yu, D., Singhal, N., Wang, G., Nayak, S. M., Weissman, C. R.

  • Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America

    Journal of Psychoactive Drugs, 2022

    Ching, T. H. W., Davis, A. K., Xin, Y., & Williams, M. T.

  • Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia

    Journal of Psychoactive Drugs, 2022

    Glynos, N. G., Pierce, J., Davis, A. K., McAfee, J., & Boehnke, K. F.

  • The Potential of Psychedelics for End of Life and Palliative Care

    Current Topics in Behavioral Neurosciences, 2022

    Yaden, D. B., Nayak, S. M., Gukasyan, N., Anderson, B. T., & Griffiths, R. R.

  • Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

    Translational Psychiatry, 2021

    Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S.

  • Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach

    Current Topics in Behavioral Neurosciences, 2021

    Agin-Liebes, G., & Davis, A. K.

  • Back to square one: the bodily roots of conscious experiences in early life

    Neuroscience of Consciousness, 2021

    Ciaunica, A., Safron, A. & Delafield-Butt, J.

  • Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms

    Current Topics in Behavioral Neurosciences, 2021

    Garcia-Romeu A., Darcy S., Jackson H., White T., Rosenberg P.

  • Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality

    Journal of Child and Adolescent Psychopharmacology, 2021

    Mathai, D. S., McCathern, A. G., Guzick, A. G., Schneider, S. C., Weinzimmer, S. A., Cepeda, S. L., Garcia-Romeu, A., & Storch, E. A.

  • Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study

    Journal of Psychoactive Drugs, 2021

    Davis, A. K., Agin-Liebes, G., España, M., Pilecki, B., & Luoma, J. B.

  • Ancient Roots of Today's Emerging Renaissance in Psychedelic Medicine

    Culture, Medicine, and Psychiatry, 2021

    George, D. R., Hanson, R., Wilkinson, D., & Garcia-Romeu, A.

  • Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States

    Journal of Psychoactive Drugs, 2021

    Davis, A. K., Agin-Liebes, G., España, M., Pilecki, B., & Luoma, J. B.

  • Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports

    Pharmacopsychiatry, 2021

    Nayak, S. M., Gukasyan, N., Barrett, F. S., Erowid, E., Erowid, F., Griffiths, R. R.

  • Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color

    Chronic Stress, 2021

    Davis, A. K., Xin, Y., Sepeda, N. D., Garcia-Romeu, A., & Williams, M. T.

  • Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs

    International Journal of Drug Policy, 2021

    Yaden, Y. B., Berghella, A. P., Regier, P. S., Garcia-Romeu, A., Johnson, M. W., & Hendricks, P. S.

  • Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities

    International Journal of Neuropsychopharmacology, 2021

    aden, Y. B., Johnson, M. W., Griffiths, R. R., Doss, M., Garcia-Romeu, A., Nayak, S., Gukasyan, N., Mathur, B. N., & Barrett, F. S.

  • Integrating Cybernetic Big Five Theory with the free energy principle: A new strategy for modeling personalities as complex systems

    Measuring and Modeling Persons and Situations, 2021

    Safron, A., & DeYoung, C. G.

  • The Radically Embodied Conscious Cybernetic Bayesian Brain: From Free Energy to Free Will and Back Again

    Entropy, 2021

    Safron, A.

  • Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives

    The American Journal of Drug and Alcohol Abuse, 2021

    Cox, D. J., Garcia-Romeu, A., & Johnson, M. W.

  • Robot navigation as hierarchical active inference

    Neural Networks, 2021

    Çatal, O., Verbelen, T., Maele, T., Dhoedt, B., Safron, A.

  • Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment

    Drugs: Education, Prevention and Policy, 2021

    Thrul, J., & Garcia-Romeu, A.

  • Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

    ACS Pharmacology & Translational Science, 2021

    Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K.

  • Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects

    ACS Pharmacology & Translational Science, 2021

    Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. M., & Davoli, C. C.

  • Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches

    Journal of Psychopharmacology, 2021

    Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R.

  • Trends in the Top-Cited Articles on Classic Psychedelics

    Journal of Psychoactive Drugs, 2021

    Lawrence, D. W., Sharma, B., Griffiths, R. R., & Carhart-Harris, R.

  • Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy

    Transcultural Psychiatry, 2021

    Gukasyan, N., & Nayak, S.

  • Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD

    Journal of Psychopharmacology, 2021

    Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R.

  • Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy

    ACS Pharmacology & Translational Science, 2021

    Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W.

  • Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine

    ACS Pharmacology & Translational Science, 2021

    Johnson, M. W.

  • The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

    ACS Pharmacology & Translational Science, 2021

    Yaden, D. B., & Griffiths, R. R.

  • People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences

    Drugs: Education, Prevention and Policy, 2021

    Williams, M. T., Davis, A. K., Xin, Y., Sepeda, N. D., Grigas, P. C., Sinnott, S., & Haeny, A. M.

  • Psychedelics and Psychotherapy

    Pharmacopsychiatry, 2021

    Nayak, S., & Johnson, M. W.

  • Psychedelics in Psychiatry–Keeping the Renaissance From Going Off the Rails

    JAMA Psychiatry, 2021

    Yaden, D. B., Yaden, M., & Griffiths, R. R.

  • Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

    JAMA Psychiatry, 2021

    Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R.

  • The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain

    Scientific Reports, 2020

    Doss, M. K., May, D. G., Johnson, M. W., Clifton, J. M., Hedrick, S. L., Prisinzano, T. E., Griffiths, R. R., & Barrett, F. S.

  • Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention

    NeuroImage, 2020

    Barrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A., & Mathur, B. N.

  • Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

    Chronic Stress, 2020

    Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T.

  • A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy

    Journal of Psychoactive Drugs, 2020

    Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R.

  • World Models and the Physical Substrates of Consciousness: Hidden Sources of the Stream of Experience?

    Journal of Consciousness Studies, 2021

    Safron, A.

  • Editorial: Hallucinogens and Entactogens: Establishing a New Class of Psychotherapeutic Drugs?

    Frontiers in Psychiatry, 2020

    Müller, F., Johnson, M. W., & Borgwardt, S.

  • Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects

    Journal of Psychopharmacology, 2020

    Davis, A. K., Clifton, J. M., Weaver, E. G., Hurwitz, E. H., Johnson, M. W., & Griffiths, R. R.

  • Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan

    Psychopharmacology, 2020

    Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R.

  • The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants

    Drug and Alcohol Dependence, 2020

    Dolan, S. B., & Johnson, M. W.

  • Long-term effects of psychedelic drugs: A systematic review

    Neuroscience & Biobehavioral Reviews, 2020

    Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C, & Davis, A. K.

  • Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects

    Journal of Psychoactive Drugs, 2020

    Lancelotta, R. & Davis, A. K.

  • Emotions and brain function are altered up to one month after a single high dose of psilocybin

    Scientific Reports, 2020

    Barrett, F. S., Doss, M. K., Sepeda N. D., Pekar J. J., & Griffiths R. R.

  • Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment

    Psychopharmacology, 2020

    Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., Ramaekers, J. G.

  • Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

    Frontiers Psychiatry, 2020

    Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W.

  • A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting

    Journal of Psychedelic Studies, 2020

    Uthaug, M. V., Lancelotta, R., Ortiz Bernal, A. M., Davis, A. K., & Ramaekers, J. G.

  • Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects

    Journal of Psychedelic Studies, 2019

    Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K.

  • Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety

    Journal of Contextual Behavioral Science, 2020

    Davis, A. K., Barrett, F. S., & Griffiths, R. R.

  • Cessation and reduction in alcohol consumption and misuse after psychedelic use

    Journal of Psychopharmacology, 2019

    Garcia-Romeu, A. Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W.

  • Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT

    PLOS ONE, 2019

    Griffiths, R. R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R.

  • 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

    The American Journal of Drug and Alcohol Abuse, 2019

    Davis, A. K., So, S., Lancelotta, R., Barsuglia, J. P., & Griffiths, R. R.

  • Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

    Frontiers Psychology, 2018

    Barsuglia, J., Davis, A. K., Palmer, R., Lancelotta, R., Windham-Herman, A. M., Peterson, K., Polanco, M., Grant, R., & Griffiths, R. R.

  • Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

    Journal of Pharmacology & Therapeutics, 2018

    Johnson, M. W., Hendricks, P. S., Barrett, F. S., Griffiths, R. R.

  • Psychiatry might need some psychedelic therapy

    International Review of Psychiatry, 2018

    Johnson, M. W.

  • Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

    International Review of Psychiatry, 2018

    Garcia-Romeu, A. G., & Richards, W. A.

  • Psychedelics and music: neuroscience and therapeutic implications

    International Review of Psychiatry, 2018

    Barrett, F. S., Preller, K. H., & Kaelen, M.

  • Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition

    Psychopharmacology, 2018

    Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R.

  • A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification

    Journal of Psychoactive Drugs, 2018

    Davis, A. K., Renn, E., Windham-Herman, A. M., Polanco, M., & Barsuglia, J. P.

  • Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

    Journal of Psychopharmacology, 2018

    Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W.

  • The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption

    Journal of Psychopharmacology, 2018

    Davis, A. K., Barsulglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E.

  • The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

    Neuropharmacology, 2018

    Johnson, M. W., Griffiths, R. R., Hendricks, P. S., Henningfield, J. E.

  • “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs

    Cannabis and Cannabinoid Research, 2018

    Barrett, F. S., Schlienz, J. N., Lembeck, N., Waqas, M., Vandrey, R.

  • Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences

    Journal of Psychopharmacology, 2018

    Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R.

  • Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

    Journal of Psychopharmacology, 2018

    Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A.

  • An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

    Journal of Psychopharmacology, 2017

    Johnson, M. J., Garcia-Romeu, A., Johnson, P. S. & Griffiths, R. R.

  • Psychedelic-associated addiction remission: An online survey

    Drug and Alcohol Dependence, 2017

    Garcia-Romeu, A., Griffiths, R. R., & , Johnson, M. W.

  • Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning

    Journal of Psychedelic Studies, 2017

    Davis, A. K., Barsuglia, J. P., Windham-Herman, A., Lynch, M., & Polanco, M.

  • Who is 'Molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves

    Journal of Psychopharmacology, 2017

    Saleemi, S., Pennybacker, S. J. Wooldridge, M., & Johnson, M. W.

  • Neuroticism is associated with challenging experiences with psilocybin mushrooms

    Personality and Individual Differences, 2017

    Barrett, F. S., Johnson, M. W., & Griffiths, R. R.

  • Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of qualitative experience

    Drug and Alcohol Dependence, 2017

    Barrett, F. S, Johnson, M. W., & Griffiths, R. R.

  • Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions

    Frontiers in Psychology, 2017

    Barrett, F. S., Robbin, H., Smooke, D., Brown, J. L., & Griffiths, R. R.

  • Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music

    Cerebral Cortex, 2017

    Barrett, F. S., Preller, K. H., Herdener, M., Janata, P., & Vollenweider, F. X.

  • Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates

    Behavioral Neurobiology of Psychedelic Drugs, 2017

    Barrett, F. S. & Griffiths, R. R.

  • Potential Therapeutic Effects of Psilocybin

    Neurotherapeutics, 2017

    Johnson, M. W. & Griffiths, R. R.

  • Long-term follow-up of psilocybin-facilitated smoking cessation

    The American Journal of Drug and Alcohol Abuse, 2017

    Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.

  • Psychedelics as Medicines: An Emerging New Paradigm

    Clinical Pharmacology & Therapeutics, 2017

    Nichols, D. E., Johnson, M. W., Nichols, C. D.

  • Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

    Journal of Psychopharmacology, 2016

    Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A.

  • Clinical Applications of Hallucinogens: A Review

    Experimental Clinical Psychopharmacology, 2016

    Garcia-Romeu, A., Kersgaard, B., & Addy, P. H.

  • The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

    Journal of Psychopharmacology, 2016

    Barrett, F. S., Bradstreet, M. P., Leoutsakos, J-M. S., Johnson, M. W. & Griffiths, R. R.

  • Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

    Journal of Psychopharmacology, 2016

    Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R.

  • Classic hallucinogens in the treatment of addictions

    Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2016

    Bogenschutz, M. P & Johnson, M. W.

  • Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans

    International Journal of Neuropsychopharmacology, 2016

    Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., Ballester, M. R., Garrido, M., González, M., Claramunt, J., Barker, S., Lomnicka, I., Waguespack, M., Johnson, M. W., Griffiths, R. R., & Riba, J.

  • Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans

    Journal of Psychopharmacology, 2016

    Johnson, M. W., MacLean, K. A., Caspers, M. J., Prisinzano, Griffiths, R. R.

  • Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

    Journal of Psychopharmacology, 2015

    Barrett, F. S., Johnson, M. W., & Griffiths, R. R.

  • LSD enhances the emotional response to music

    Journal of Psychopharmacology, 2015

    Kaelen, M., Barrett, F. S., Roseman, R., Lorenz, R., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L.

  • Can psychedelic compounds play a part in drug dependence therapy?

    The British Journal of Psychiatry, 2015

    Sessa, B. & Johnson, M. W.

  • The challenging experience questionnaire: Characterization of acute adverse reactions to psilocybin

    Drug and Alcohol Dependence, 2015

    Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. S., Johnson, M. W., MacLean, K. A., Jess, R., & Griffiths, R. R.

  • Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology

    Drug and Alcohol Dependence, 2015

    Carbonaro, T., Barrett, F., Bradstreet, M. P., Johnson, M. W., MacLean, K. A., Jess, R., & Griffiths, R. R.

  • Psilocybin, psychological distress, and suicidality

    Journal of Psychopharmacology, 2015

    Hendricks, P. S., Johnson, M. W., & Griffiths, R. R.

  • Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

    Journal of Psychopharmacology, 2015

    Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., &, Johnson, M. W.

  • Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

    Current Drug Abuse Reviews, 2015

    Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W.

  • Psychedelic medicine: a re-emerging therapeutic paradigm

    Canadian Medical Journal, 2015

    Tupper, K., Wood, E, Yensen, R., Johnson, M. W.

  • Hallucinogens and club drugs

    The American Psychiatric Publishing Textbook of Substance Abuse, 2015

    MacLean, K. A., Johnson, M. W., & Griffiths, R. R.

  • Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

    Journal of Psychopharmacology, 2014

    Hendricks, P., Clark, C., Johnson, M. W.

  • Psilocybin research at Johns Hopkins: A 2014 report

    Seeking the Sacred with Psychoactive Substances, Volume 2, 2014

    Jesse, R. and Griffiths, R. R.

  • Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

    Journal of Psychopharmacology, 2014

    Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R.

  • LC-MS/MS quantification of salvinorin A from biological fluids

    Analytical Methods, 2013

    Caspers, M. J., Williams, T. D., Lovell, K. M. Lozama, A., Butelman, E. R., Kreek, M. J., Johnson, M., Griffiths, R., MacLean, K., & Prisinzano, T. E.

  • Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

    Psychopharmacology, 2013

    MacLean, K. A., Johnson, M. W., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R.

  • Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer

    Psychological Aspects of Cancer, 2013

    Grob, C. S., Bossis, A. P. & Griffiths, R. R.

  • Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin

    Journal for the Scientific Study of Religion, 2012

    MacLean, K. A., Leoutsakos, J-M. S., Johnson, M. W., & Griffiths, R. R.

  • Hallucinogens

    Encyclopedia of Lifestyle Medicine and Health, Volume 1, 2012

    Johnson M. W.

  • High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens

    Psychopharmacology, 2012

    Reissig, C. J., Carter, L. P., Johnson, M. W., Mintzer, M. Z., Klinedinst, M. A. & Griffiths, R. R.

  • Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers

    Drug and Alcohol Dependence, 2012

    Johnson, M.W., Sewell, R.A, & Griffiths, R.R.

  • Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

    Journal of Psychopharmacology

    MacLean, K. A., Johnson, M. W., & Griffiths, R. R.

  • Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

    Psychopharmacology, 2011

    Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.

  • Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

    Drug and Alcohol Dependence, 2011

    Johnson, M. W. MacLean, K. A., Reissig, C. J., Prisinzano, T. E. & Griffiths, R. R.

  • Salvia Divinorum

    Encyclopedia of Drug Policy, Volume 2, 2011

    Johnson M. W.

  • Hallucinogens as medicine

    Scientific American, 2010

    Griffiths, R. R. & Grob, C. S.

  • Human hallucinogen research: guidelines for safety

    Journal of Psychopharmacology, 2008

    Johnson, M. W., Richards, W. A., & Griffiths, R. R.

  • Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

    Journal of Psychopharmacology, 2008

    Griffiths, R. R., Johnson, M. W., Richards, W. A., McCann, U., & Richards, B. D.

  • Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

    Psychopharmacology, 2006

    Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R.

  • Exploring serotonergic psychedelics as a treatment for personality disorders

    Neuropharmacology, 2025

    Carrithers, B. M., Roberts, D. E., Weiss, B. M., King, J. D., Carhart-Harris, R. L., Gordon, A. R., Pagni, B. A., Moreau, M., Ross, S., Zeifman, R. J.